Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.90
Bid: 29.10
Ask: 30.70
Change: 0.10 (0.34%)
Spread: 1.60 (5.498%)
Open: 29.80
High: 0.00
Low: 0.00
Prev. Close: 29.80
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) (EKF Diagnostics Holdings plc)

2 Sep 2015 10:54

RNS Number : 8316X
EKF Diagnostics Holdings PLC
02 September 2015
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

EKF Diagnostics Holdings plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

OFFEREE - EKF Diagnostics Holdings plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

28 August 2015

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

1p ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

-

0

-

(2) Cash-settled derivatives:

 

0

-

0

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

-

0

-

 

TOTAL:

0

-

0

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None.

Details, including nature of the rights concerned and relevant percentages:

None.

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

3(a) Interests of directors of EKF Diagnostics Holdings plc in EKF Diagnostics Holdings plc ordinary shares

 

Director

Number of EKF Diagnostics Holdings plc Ordinary Shares

% of EKF Diagnostics Holdings plc Issued Ordinary Share Capital

Paul Foulger

3,488,589

0.83

Adam Reynolds

3,229,724

0.77

David Evans

1,805,753

0.43

Julian Baines

1,721,955

0.41

Kevin Wilson

947,846

0.22

Richard Evans

178,842

0.04

Tito Bacarese-Hamilton

106,429

0.03

TOTAL

11,479,138

2.72

 

3(b) Interests in EKF Diagnostics Holdings plc shares held by directors in awards of ordinary shares under EKF Diagnostics Holdings plc's share plans

 

Name

Number of Options

Date from which exercisable

Expiry date

Exercise price (p)

 
 

Paul Foulger*

1,000,000

17-Apr-17

17-Apr-24

35

 

David Evans*

8,545,638

01-Jan-14

31-Dec-20

15

 

Julian Baines*

8,545,638

01-Jan-14

31-Dec-20

15

 

Richard Evans

4,260,000

01-Jan-14

31-Dec-20

20

 

Tito Bacarese-Hamilton

1,300,000

30-May-17

30-May-24

35

 

 

*Some of these shares are subject to certain share price performance conditions which are documented fully in the company's Annual Report.

 

3(c) Interests of connected advisors

 

Panmure Gordon (UK) Limited

 

Class of relevant security:

 

1p ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

-

-

-

-

(2) Derivatives (other than options):

-

-

-

-

(3) Options and agreements to purchase/sell:

-

-

-

-

 

TOTAL:

-

-

-

-

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None.

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None.

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

2 September 2015

Contact name:

Paul Foulger

Telephone number:

+44 (0)1932 220 124

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEESSFSUEFISEIU
Date   Source Headline
22nd Apr 202411:53 amRNSPosting of Annual Report & Notice of AGM
25th Mar 20245:15 pmRNSDirector/PDMR Shareholding
20th Mar 20248:30 amRNSFinal Results
15th Mar 20247:00 amRNSInvestor Presentation – Revised start time
11th Mar 20247:00 amRNSNotice of Results and Investor Presentation
29th Jan 20247:00 amRNSTrading Update
11th Jan 20247:00 amRNSDirector/PDMR Shareholding
3rd Jan 20244:14 pmRNSHolding(s) in Company
29th Nov 20234:55 pmRNSHolding(s) in Company
26th Oct 20237:00 amRNSOpening of new US LS Manufacturing Facility
26th Sep 20237:00 amRNSInterim results
14th Sep 20237:00 amRNSNotice of Results & Investor Presentation
12th Sep 20237:01 amRNSTrading Update
12th Sep 20237:00 amRNSAppointment of CFO
26th Jul 20237:00 amRNSTrading Update
28th Jun 20237:00 amRNSDirectorate Change
20th Jun 20237:00 amRNSEnzyme fermentation capacity expansion progress
1st Jun 202311:07 amRNSHolding(s) in Company
24th May 20237:01 amRNSUpdate re. EKF distribution of shares in Verici Dx
24th May 20237:00 amRNSDistribution of shares in Verici Dx plc
22nd May 20232:52 pmRNSHolding(s) in Company
17th May 202311:50 amRNSResult of AGM and Voting Results
17th May 20237:00 amRNSAGM Statement
3rd May 20237:00 amRNSSuccessful quality management audits
25th Apr 20234:10 pmRNSTotal Voting Rights
21st Apr 20232:30 pmRNSPosting of Annual Report & Notice of AGM
28th Mar 20237:00 amRNSFinal Results
23rd Mar 20237:00 amRNSDisposal of ADL Health
1st Mar 20237:00 amRNSNotice of Results and Investor Presentation
21st Feb 20233:31 pmRNSHolding(s) in Company
10th Feb 20233:12 pmRNSHolding(s) in Company
6th Feb 20237:00 amRNSTrading update
9th Jan 20237:00 amRNSChange of Adviser
22nd Dec 20224:40 pmRNSSecond Price Monitoring Extn
22nd Dec 20224:35 pmRNSPrice Monitoring Extension
22nd Dec 20227:00 amRNSPoint-of-Care update
15th Dec 20224:52 pmRNSHolding(s) in Company
14th Dec 20224:32 pmRNSHolding(s) in Company
6th Dec 20225:30 pmRNSHolding(s) in Company
14th Nov 20225:52 pmRNSHolding(s) in Company
20th Sep 20227:01 amRNSDividend Timetable
20th Sep 20227:00 amRNSHalf-year Report
1st Sep 20227:00 amRNSNotice of Interim Results & Investor Presentation
1st Aug 20227:00 amRNSTrading Update
29th Jun 20224:41 pmRNSSecond Price Monitoring Extn
29th Jun 20224:36 pmRNSPrice Monitoring Extension
28th Jun 20223:34 pmRNSHolding(s) in Company
22nd Jun 20224:36 pmRNSPrice Monitoring Extension
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
20th Jun 20227:00 amRNSDistribution of shares in Verici Dx plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.